This study aimed to evaluate the methylation status of a specific CpG dinucleotide (cg11346722) in the SPDEF gene promoter as a novel, cancer-specific epigenetic biomarker with both diagnostic and prognostic potential for prostate cancer. This evidence concerns the gene SPDEF and prostate carcinoma.